Literature DB >> 9422987

Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours.

Y Dong1, M D Walsh, M C Cummings, R G Wright, S K Khoo, P G Parsons, M A McGuckin.   

Abstract

This is the first study to describe the association between expression of MUC1 and MUC2 mucins and prognosis in ovarian cancer. Paraffin sections of epithelial ovarian tumours (n = 182: 29 benign, 21 low malignant potential, and 132 invasive tumours) were analysed immunohistochemically for expression of MUC1 and MUC2 mucin core proteins. Most benign, low malignant potential, and invasive tumours showed high MUC1 expression in the cytoplasm. Low cytoplasmic expression of MUC1 was a predictor for good prognosis, particularly within stage III tumours. A minority of benign epithelial tumours, but most low malignant potential and invasive non-mucinous tumours, showed high MUC1 expression on the cell membrane. High apical MUC1 reactivity was associated with non-mucinous tumours. Low expression of MUC1 in the apical membrane was associated with early stage and good outcome for invasive tumours. Most benign and low malignant potential tumours, but only a minority of invasive tumours, showed MUC2 expression. MUC2 was found in non-mucinous as well as in mucinous tumours. The presence of MUC2 was inversely associated with high tumour grade but was not associated with altered survival. These results support experimental evidence that MUC1 influences the metastatic ability of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9422987     DOI: 10.1002/(SICI)1096-9896(199711)183:3<311::AID-PATH917>3.0.CO;2-2

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  30 in total

Review 1.  Glycosylation alterations in lung and brain cancer.

Authors:  Hassan Lemjabbar-Alaoui; Andrew McKinney; Yi-Wei Yang; Vy M Tran; Joanna J Phillips
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

Review 2.  Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer.

Authors:  Ajay P Singh; Shantibhusan Senapati; Moorthy P Ponnusamy; Maneesh Jain; Subodh M Lele; John S Davis; Steven Remmenga; Surinder K Batra
Journal:  Lancet Oncol       Date:  2008-11       Impact factor: 41.316

3.  Absence of correlation of MUC1 expression to malignant behavior of renal cell carcinoma in experimental systems.

Authors:  K Denda-Nagai; K Fujita; M Fujime; S Nakatsugawa; T Ishigaki; T Irimura
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.

Authors:  R L ten Berge; F G Snijdewint; S von Mensdorff-Pouilly; R J Poort-Keesom; J J Oudejans; J W Meijer; R Willemze; J Hilgers; C J Meijer
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

Review 5.  Mucin 13: structure, function, and potential roles in cancer pathogenesis.

Authors:  Diane M Maher; Brij K Gupta; Satoshi Nagata; Meena Jaggi; Subhash C Chauhan
Journal:  Mol Cancer Res       Date:  2011-03-30       Impact factor: 5.852

6.  Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary.

Authors:  Dirk Bauerschlag; Karen Bräutigam; Roland Moll; Jalid Sehouli; Alexander Mustea; Darius Salehin; Maryla Krajewska; John C Reed; Nicolai Maass; Garret M Hampton; Ivo Meinhold-Heerlein
Journal:  J Cancer Res Clin Oncol       Date:  2012-10-23       Impact factor: 4.553

Review 7.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

8.  Loss of MUC2 expression predicts disease recurrence and poor outcome in colorectal carcinoma.

Authors:  Adam Elzagheid; Fatma Emaetig; Abdelbaset Buhmeida; Matti Laato; Omran El-Faitori; Kari Syrjänen; Yrjö Collan; Seppo Pyrhönen
Journal:  Tumour Biol       Date:  2012-11-21

Review 9.  Glycosylation Changes in Brain Cancer.

Authors:  Lucas Veillon; Christina Fakih; Hadi Abou-El-Hassan; Firas Kobeissy; Yehia Mechref
Journal:  ACS Chem Neurosci       Date:  2017-11-07       Impact factor: 4.418

10.  Mucins in ovarian cancer diagnosis and therapy.

Authors:  Subhash C Chauhan; Deepak Kumar; Meena Jaggi
Journal:  J Ovarian Res       Date:  2009-12-24       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.